Cargando…

Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation

In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Urasaki, Yasuyo, Le, Thuc T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416494/
https://www.ncbi.nlm.nih.gov/pubmed/36014807
http://dx.doi.org/10.3390/nu14163301
_version_ 1784776494127513600
author Urasaki, Yasuyo
Le, Thuc T.
author_facet Urasaki, Yasuyo
Le, Thuc T.
author_sort Urasaki, Yasuyo
collection PubMed
description In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no effect on Akt2 phosphorylation at S474, which is critical for Akt2 activation. Surprisingly, insulin treatment with cinnamaldehyde or curcumin increased p-Akt2 (S474) by 3.5-fold versus insulin treatment alone. Furthermore, combined cinnamaldehyde, curcumin, and insulin treatment increased p-Akt2 (S474) by 7-fold versus insulin treatment alone. Interestingly, cinnamaldehyde and curcumin inhibited both serine/threonine phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B). Akt2 activation is a multistep process that requires phosphorylation at T450 for proper folding and maturation, and phosphorylation of both Y475 and S474 for stabilization of the catalytic domain. It is plausible that by inhibiting PP2A and PTP1B, cinnamaldehyde and curcumin increase phosphorylation at T450 and Y475, and prime Akt2 for insulin-stimulated phosphorylation at S474. Notably, the combination of a PP2A inhibitor, okadaic acid, and a PTP1B inhibitor increased p-Akt2 (S474), even in the absence of insulin. Future combinations of PP2A and PTP1B inhibitors provide a rational platform to engineer new therapeutics for insulin resistance syndrome.
format Online
Article
Text
id pubmed-9416494
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94164942022-08-27 Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation Urasaki, Yasuyo Le, Thuc T. Nutrients Article In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no effect on Akt2 phosphorylation at S474, which is critical for Akt2 activation. Surprisingly, insulin treatment with cinnamaldehyde or curcumin increased p-Akt2 (S474) by 3.5-fold versus insulin treatment alone. Furthermore, combined cinnamaldehyde, curcumin, and insulin treatment increased p-Akt2 (S474) by 7-fold versus insulin treatment alone. Interestingly, cinnamaldehyde and curcumin inhibited both serine/threonine phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B). Akt2 activation is a multistep process that requires phosphorylation at T450 for proper folding and maturation, and phosphorylation of both Y475 and S474 for stabilization of the catalytic domain. It is plausible that by inhibiting PP2A and PTP1B, cinnamaldehyde and curcumin increase phosphorylation at T450 and Y475, and prime Akt2 for insulin-stimulated phosphorylation at S474. Notably, the combination of a PP2A inhibitor, okadaic acid, and a PTP1B inhibitor increased p-Akt2 (S474), even in the absence of insulin. Future combinations of PP2A and PTP1B inhibitors provide a rational platform to engineer new therapeutics for insulin resistance syndrome. MDPI 2022-08-12 /pmc/articles/PMC9416494/ /pubmed/36014807 http://dx.doi.org/10.3390/nu14163301 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Urasaki, Yasuyo
Le, Thuc T.
Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title_full Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title_fullStr Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title_full_unstemmed Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title_short Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
title_sort cinnamaldehyde and curcumin prime akt2 for insulin-stimulated activation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416494/
https://www.ncbi.nlm.nih.gov/pubmed/36014807
http://dx.doi.org/10.3390/nu14163301
work_keys_str_mv AT urasakiyasuyo cinnamaldehydeandcurcuminprimeakt2forinsulinstimulatedactivation
AT lethuct cinnamaldehydeandcurcuminprimeakt2forinsulinstimulatedactivation